中山大学李旭日（Xuri Li）和Peter Carmeliet等研究人员在2019年9月3日出版的《细胞—代谢》发表综述，总结了内皮细胞代谢在健康和疾病中的特征。

综述说，在2009年，人们认为如果内皮细胞（EC）相应地适应其新陈代谢，就只能执行生长因子的指令。十年后，很明显EC（通常与其他细胞类型不同）依赖于不同的代谢途径来生存并形成新的血管；单独操纵EC代谢途径（即使不改变血管生成信号）也足以改变血管发芽；并且这些代谢途径的扰动可以成为癌症和眼部疾病中新血管（血管生成）的过度形成的基础。

目前的研究已经提供了初步证据，即靶向（正常化）患病EC中的这些代谢扰动和代谢物的递送，作为用于抑制或刺激多种病症中的血管生长的新型治疗方法，值得越来越多的关注。

附：英文原文

Title: Hallmarks of Endothelial Cell Metabolism in Health and Disease

Author: Xuri Li, Xiaodong Sun, Peter Carmeliet

Issue&Volume: Volume 30 Issue 3

Abstract: In 2009, it was postulated that endothelial cells (ECs) would only be able to execute the orders of growth factors if these cells would accordingly adapt their metabolism. Ten years later, it has become clear that ECs, often differently from other cell types, rely on distinct metabolic pathways to survive and form new blood vessels; that manipulation of EC metabolic pathways alone (even without changing angiogenic signaling) suffices to alter vessel sprouting; and that perturbations of these metabolic pathways can underlie excess formation of new blood vessels (angiogenesis) in cancer and ocular diseases. Initial proof of evidence has been provided that targeting (normalizing) these metabolic perturbations in diseased ECs and delivery of metabolites deserve increasing attention as novel therapeutic approaches for inhibiting or stimulating vessel growth in multiple disorders.

DOI: https://doi.org/10.1016/j.cmet.2019.08.011

Source: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(19)30440-1#